Willoughby Scott B., Senior Vice President, General Counsel, and Secretary, has engaged exclusively in selling activity involving shares of Sangamo Therapeutics (SGMO) over the past two years, according to SEC Form 4 filings. The transactions, totaling $263,564.12 in aggregate value, show a consistent pattern of periodic disposals, with no recorded purchases during this period. The largest single sale occurred on January 22, 2025, when Willoughby divested shares worth $148,981.35, followed by a $29,120.52 transaction on October 22, 2025, and a $24,737.58 sale on April 22, 2025. Smaller, more frequent sales—often under $3,000—appear clustered around late February, May, August, and November, suggesting possible routine dispositions tied to equity compensation or tax planning.
Notably, the most recent transactions—dated February 24 and 25, 2026—involved sales of $779.63 and $5,806.38, respectively, continuing the trend of periodic reductions. The filings indicate that all transactions were coded as "F," representing sales under Rule 16b-3, typically involving employee benefit plan-related dispositions. While the activity reflects a clear divestment bias, the absence of purchases and the structured timing of sales do not suggest abrupt changes in position. Willoughby’s trading history remains confined to SGMO, with no activity in other securities over the reported period. The pattern aligns with gradual unwinding rather than concentrated liquidation, though the lack of buy-side activity distinguishes it from more balanced insider trading profiles.
AI-assisted summary